PMID- 21733227
OWN - NLM
STAT- MEDLINE
DCOM- 20120730
LR  - 20161020
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Linking)
VI  - 14
IP  - 10
DP  - 2011 Nov
TI  - Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val(6)(6)Met 
      polymorphism is associated with a better response to OROS-MPH in Korean ADHD 
      children.
PG  - 1399-410
LID - 10.1017/S146114571100099X [doi]
AB  - Research on psychostimulants, analysis of animal models and genetic association 
      studies all suggest that the brain-derived neurotrophic factor gene (BDNF) may be 
      a good candidate for pharmacogenetic studies of attention deficit hyperactivity 
      disorder (ADHD). Yet to date there have been no pharmacogenetic studies of BDNF 
      in ADHD. A total of 102 drug-naive ADHD children (8.7+/-2.1 yr) were treated with 
      osmotic release oral system-methylphenidate (OROS-MPH) for 12 wk, and four kinds 
      of response criteria were applied, based first, on a combined threshold of the 
      ADHD Rating Scale - IV (ARS) and the Clinical Global Impression - Improvement 
      scale (CGI-I); second, on scores of 1 or 2 vs. 3-7 on the CGI - Severity scale; 
      third, on a >50% reduction in ARS scores; and fourth, on satisfaction of all of 
      the aforementioned criteria. The Val(6)(6)Met polymorphism of BDNF and six single 
      nucleotide polymorphisms from the SLC6A2, ADRA2A and NTF-3 genes were tested for 
      association with each criterion. Relative to other genotypes, homozygosity for 
      the Val allele of the BDNF Val(6)(6)Met polymorphism was associated with a greater 
      relative frequency of good response under all four response criteria (after 
      controlling for baseline ARS score, age, gender, final dose (mg/kg) of OROS-MPH 
      at 12 wk, and level of academic functioning). This association was significant at 
      the uncorrected level for the first and third response criteria (p=0.013 and 
      p=0.018, respectively) and significant at a Bonferroni-corrected level for the 
      second and fourth response criteria (p=0.0002, p=0.0003, respectively). Our 
      findings support an association between homozygosity for the Val allele of BDNF 
      and better response to OROS-MPH in Korean ADHD children as assessed by four 
      different response criteria.
FAU - Kim, Bung-Nyun
AU  - Kim BN
AD  - Division of Child and Adolescent Psychiatry, Department of Psychiatry, College of 
      Medicine, Seoul National University, Seoul, Korea.
FAU - Cummins, Tarrant D R
AU  - Cummins TD
FAU - Kim, Jae-Won
AU  - Kim JW
FAU - Bellgrove, Mark A
AU  - Bellgrove MA
FAU - Hong, Soon-Beom
AU  - Hong SB
FAU - Song, Sook-Hyung
AU  - Song SH
FAU - Shin, Min-Sup
AU  - Shin MS
FAU - Cho, Soo-Churl
AU  - Cho SC
FAU - Kim, Ji-Hoon
AU  - Kim JH
FAU - Son, Jung-Woo
AU  - Son JW
FAU - Shin, Yun-Mi
AU  - Shin YM
FAU - Chung, Un-Sun
AU  - Chung US
FAU - Han, Doug-Hyun
AU  - Han DH
LA  - eng
SI  - ClinicalTrials.gov/NCT01012622
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110628
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Delayed-Action Preparations)
RN  - 207ZZ9QZ49 (Methylphenidate)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Administration, Oral
MH  - Age Factors
MH  - Analysis of Variance
MH  - Attention Deficit Disorder with Hyperactivity/diagnosis/*drug 
      therapy/*genetics/psychology
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Central Nervous System Stimulants/*administration & dosage
MH  - Chi-Square Distribution
MH  - Child
MH  - Child Behavior/*drug effects
MH  - Delayed-Action Preparations
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Homozygote
MH  - Humans
MH  - Male
MH  - Methylphenidate/*administration & dosage
MH  - Pharmacogenetics
MH  - Phenotype
MH  - *Polymorphism, Single Nucleotide
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - Regression Analysis
MH  - Republic of Korea
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valine
EDAT- 2011/07/08 06:00
MHDA- 2012/07/31 06:00
CRDT- 2011/07/08 06:00
PHST- 2011/07/08 06:00 [entrez]
PHST- 2011/07/08 06:00 [pubmed]
PHST- 2012/07/31 06:00 [medline]
AID - S146114571100099X [pii]
AID - 10.1017/S146114571100099X [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2011 Nov;14(10):1399-410. doi: 
      10.1017/S146114571100099X. Epub 2011 Jun 28.